CoChat

Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers

Open access
Seguin, Laetitia, Camargo, Maria F., Wettersten, Hiromi I., Kato, Shumei, Desgrosellier, Jay S., von Schalscha, Tami, Elliott, Kathryn C., Cosset, Erika, Lesperance, Jacqueline, Weis, Sara M., Cheresh, David A. · 2017 · Cancer Discovery
Cited by 102

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Identifying the molecular basis for cancer cell dependence on oncogenes such as KRAS can provide new opportunities to target these addictions. Here, we identify a novel role for the carbohydrate-binding protein galectin-3 as a lynchpin for KRAS dependence. By directly binding to the cell surface receptor integrin αvβ3, galectin-3 gives rise to KRAS addiction by enabling multiple functions of KRAS in anchorage-independent cells, including formation of macropinosomes that facilitate nutrient uptake and ability to maintain redox balance. Disrupting αvβ3/galectin-3 binding with a clinically active drug prevents their association with mutant KRAS, thereby suppressing macropinocytosis while increasing reactive oxygen species to eradicate αvβ3-expressing KRAS-mutant lung and pancreatic cancer patient–derived xenografts and spontaneous tumors in mice. Our work reveals galectin-3 as a druggable target for KRAS-addicted lung and pancreas cancers, and indicates integrin αvβ3 as a biomarker to identify susceptible tumors. Significance: There is a significant unmet need for therapies targeting KRAS-mutant cancers. Here, we identify integrin αvβ3 as a biomarker to identify mutant KRAS–addicted tumors that are highly sensitive to inhibition of galectin-3, a glycoprotein that binds to integrin αvβ3 to promote KRAS-mediated activation of AKT. Cancer Discov; 7(12); 1464–79. ©2017 AACR. This article is highlighted in the In This Issue feature, p. 1355

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-17-0539

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 102

Metadata

Authors
Seguin, L., Camargo, M. F., Wettersten, H. I., Kato, S., Desgrosellier, J. S., von Schalscha, T., Elliott, K. C., Cosset, E., Lesperance, J., Weis, S. M., & Cheresh, D. A.
Venue
Cancer Discovery
Published
2017-12-01
Volume
7
Issue
12
Pages
1464-1479
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2755492550
Cited by
102
References
16
FWCI
4.71
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers. https://app.cochat.ai/papers/10.1158/2159-8290.cd-17-0539
The paper
Seguin, L., Camargo, M. F., Wettersten, H. I., Kato, S., Desgrosellier, J. S., von Schalscha, T., Elliott, K. C., Cosset, E., Lesperance, J., Weis, S. M., & Cheresh, D. A. (2017). Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-17-0539

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.